A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis
Main Article Content
Keywords
Psoriasis, Calcipotriene, Corticosteroid, Halobetasol
Abstract
References
2. Silverberg, N B 2009 Pediatric Psoriasis An Update Therapeutics and Clinical Risk Management, 5 849-856
3. Kimball, A Gold, M Zib B Davis, M Clobetasol Propionate Emulsion Formulation Foam Ph 2008 Clobetasol propionate emulsion formulation foam 0 05 review of phase II open label and phase III randomized controlled trials in steroid responsive dermatoses in adults and adolescents JAAD, 59 3 448 454
4. Shah, K N 2013 Diagnosis and Treatment of Pediatric Psoriasis Current and Future American Journal of Clinical Dermatology, 14 195
5. Wolverton S E 2001 Comprehensive Dermatologic Drug Therapy XlX ed Philadelphia, PA Saunders
6 Feldman S R Mills, M Brundage, T Eastman, W J 2013 March) A multicenter, randomized, double blind study of the efficacy and safety of calcipotriene foam, 0 005 vs vehicle foam in the treatment of plaque type psoriasis of the scalp JDD, 12 3 300 306
7 Hebert, A Glaab, D Schrieber R 2019 A Phase 1 Open Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0 005 Applied Under Maximum Use Conditions in Adolescent Subjects with Plaque Psoriasis SKIN The Journal of Cutaneous Medicine, 3 2
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.